Gefitinib as an antimalarial: unveiling its therapeutic potential
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-01682-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Varun Gorki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India. Hauptthemen laut MEDLINE: Antimalarials, Gefitinib, Malaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: University Grants Commission.
Abstract (Originalsprache)
Resistant strains of Plasmodium spp. pose a great threat to healthcare. Drug repurposing is a smart, and an effective way to look for new alternatives for different ailments including malaria. Protein tyrosine kinases (PTKs) play a crucial role in growth, maturation as well as differentiation of Plasmodium and this study explores antimalarial activity of PTKs inhibitor gefitinib using in silico and experimental approaches. The drug showed considerable inhibitory activity against P. falciparum 3D7 (IC50 0.49 µg/mL) and RKL-9 (IC50 0.83 µg/mL) strains. Isobologram analysis revealed substantial synergism between gefitinib and artesunate. Gefitinib illustrated highest negative D-score towards phosphoethanolamine methyltransferase followed by PfPK5 and CDPK1. Its acute toxicity was 4 g/kg. Gefitinib (100 mg/kg) exhibited a dose-dependent curative activity against P. berghei with 91.09% chemo-suppression and the combination of gefitinib 100 mg/kg and AS 50 mg/kg exhibited complete parasite clearance with no recrudescence which was also evidenced by cytokine analysis, biochemical as well as histopathological studies. At length, gefitinib illustrated considerable antiplasmodial action by targeting phosphoethanolamine methyltransferase, PfPK5 and CDPK1. The combination of gefitinib (100 mg/kg) and AS (50 mg/kg) holds promise for malaria treatment. Further, research is being done to evaluate its pharmacokinetic properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India.
- Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
- Department of Biophysics, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
- University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
- Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India. sukhbir@pu.ac.in.
Förderung
- University Grants Commission
Zitieren
APA
Gorki, V., Walter, N. S., Chauhan, M., Dhingra, N., Bagai, U., & Kaur, S. (2025). Gefitinib as an antimalarial: unveiling its therapeutic potential. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01682-5
Vancouver
Gorki V, Walter NS, Chauhan M, Dhingra N, Bagai U, Kaur S. Gefitinib as an antimalarial: unveiling its therapeutic potential. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01682-5
BibTeX
@article{Gorki2025,
author = {Gorki, Varun and Walter, Neha Sylvia and Chauhan, Monika and Dhingra, Neelima and Bagai, Upma and Kaur, Sukhbir},
title = {Gefitinib as an antimalarial: unveiling its therapeutic potential},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-01682-5}
}
EUVIMED